First and final report of a phase II study of the poly(ADP-ribose) polymerase (PARP) inhibitor, AGO14699, in combination with temozolomide (TMZ) in patients with metastatic malignant melanoma (MM)

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.

Author(s): Plummer ER, Lorigan P, Evans J, Steven N, Middleton M, Wilson R, Snow K, Dewji R, Calvert AH

Publication type: Article

Publication status: Published

Journal: Journal of Clinical Oncology

Year: 2006

Volume: 24

Issue: 18 (Part 1 Suppl. S)

Pages: 456S-456S

ISSN (print): 0732-183X

ISSN (electronic): 1527-7755

Notes: From conference: 42nd Annual Meeting of the American Society of Clinical Oncology, 02-06 June 2006, Atlanta, GA.

ePrints